Elliott L. Fineman
Vorstandsvorsitzender bei Planet Biotechnology, Inc.
Aktive Positionen von Elliott L. Fineman
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Planet Biotechnology, Inc.
 Planet Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Planet Biotechnology, Inc. identifies and develops promising antibodies and receptor-antibody fusion molecules for the treatment and prevention of infectious diseases including emerging diseases and bio-threat agents. The company was is headquartered in Hayward, CA. | Vorstandsvorsitzender | 01.01.1998 | - |
| Präsident | 01.01.1998 | - |
Karriereverlauf von Elliott L. Fineman
Ehemalige bekannte Positionen von Elliott L. Fineman
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
SuperGen, Inc.
 SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Gründer | 16.07.2009 | 13.09.2011 |
| Corporate Officer/Principal | 06.03.1991 | 16.07.2009 | |
| Cetus Corp. | Corporate Officer/Principal | - | - |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Geschäftsführer | - | - |
Ausbildung von Elliott L. Fineman
| University of Baltimore | Graduate Degree |
| Georgetown University | Graduate Degree |
| Oberlin College | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
Operativ
| Graduate Degree | 2 |
| Corporate Officer/Principal | 2 |
| Chief Executive Officer | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Planet Biotechnology, Inc.
Planet Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Planet Biotechnology, Inc. identifies and develops promising antibodies and receptor-antibody fusion molecules for the treatment and prevention of infectious diseases including emerging diseases and bio-threat agents. The company was is headquartered in Hayward, CA. | Health Technology |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Health Technology |
| Cetus Corp. | Health Technology |
- Börse
- Insiders
- Elliott L. Fineman
- Erfahrung
